Bausch Health Companies (BHC) Net Margin (2009 - 2026)
Bausch Health Companies' (BHC) quarterly Net Margin came in at 9.12% in Q2 2026, up 406.0% year-over-year from 1.8% in Q2 2025, and up 116.08% quarter-over-quarter from 56.7% in Q1 2026.
Analysis
Bausch Health Companies (BHC) Net Margin (2009 - 2026) Analysis & Trends
Bausch Health Companies has disclosed Net Margin across 18 years of filings, most recently posting 9.12% for Q2 2026.
- In Q2 2026, Net Margin rose 406.0% year-over-year to 9.12%; the TTM figure through Jun 2026 stood at 10.07% (down 1056.0% YoY), while the FY2025 annual figure was 1.17%, up 192.0% from the prior year.
- Net Margin came in at 9.12% for Q2 2026 at Bausch Health Companies, up from 56.7% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 19.7% in Q3 2022 to a low of 56.7% in Q1 2026.
- Average Net Margin over 5 years is 4.71%, with a median of 3.51% recorded in 2022.
- Year-over-year, Net Margin soared 2650 bps in 2022 and plunged 5289 bps in 2026.
- Over 5 years, Net Margin stood at 18.7% in 2022, then soared by 90 bps to 1.95% in 2023, then surged by 296 bps to 3.83% in 2024, then tumbled by 196 bps to 3.68% in 2025, then jumped by 347 bps to 9.12% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 9.12% in Q2 2026, 56.7% in Q1 2026, and 3.68% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.23 Bn | 38.58 Bn | 2.15 Bn | -13.91% |
| 2 | Viatris | 18.97 Bn | 18.08 Bn | 1.46 Bn | -3.16% |
| 3 | Dr Reddys Laboratories | 9.80 Bn | 9.63 Bn | 396.53 Mn | 5.50% |
| 4 | Amneal Pharmaceuticals | 5.39 Bn | 5.26 Bn | 334.51 Mn | 8.74% |
| 5 | Bausch Health Companies | 2.28 Bn | 443.88 Mn | 2.10 Bn | 9.12% |
| 6 | Alvotech | 1.53 Bn | 1.39 Bn | 2.56 Mn | -121.81% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 9.28% |
| 8 | Amphastar Pharmaceuticals | 1.02 Bn | 728.53 Mn | 93.47 Mn | 16.50% |
| 9 | Fennec Pharmaceuticals | 392.67 Mn | 351.42 Mn | 17.15 Mn | 11.04% |
| 10 | RedHill Biopharma | 172.24 Mn | 172.24 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.12% |
| Mar 31, 2026 | -56.70% |
| Dec 31, 2025 | -3.68% |
| Sep 30, 2025 | 6.75% |
| Jun 30, 2025 | 5.06% |
| Mar 31, 2025 | -3.81% |
| Dec 31, 2024 | 3.83% |
| Sep 30, 2024 | -3.67% |
| Jun 30, 2024 | -0.04% |
| Mar 31, 2024 | -3.58% |
| Dec 31, 2023 | -1.95% |
| Sep 30, 2023 | -17.07% |
| Jun 30, 2023 | 1.25% |
| Mar 31, 2023 | -10.75% |
| Dec 31, 2022 | -18.70% |
| Sep 30, 2022 | 19.70% |
| Jun 30, 2022 | -7.07% |
| Mar 31, 2022 | -3.44% |
| Dec 31, 2021 | 3.28% |
| Sep 30, 2021 | 9.05% |